Skip to main content
SpringerLink
Log in

Depression in Parkinson’s disease

  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

Depression is common in Parkinson’s disease (PD), and its identification and treatment are critically important in disease management. Despite depression’s high prevalence and major impact on patient quality of life, questions remain regarding its epidemiology and preferred treatment. The authors of this paper summarize available information on the epidemiology of depression in PD, review treatment options, and discuss possible interactions between antidepressants and other agents. This information may help guide clinical treatment and define the need for further studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Hantz P, Caradoc-Davies G, Caradoc-Davies T, et al.: Depression in Parkinson’s disease. Am J Psychiatry 1994, 151:1010–1014.

    PubMed  CAS  Google Scholar 

  2. Starkstein SE, Preziosi TJ, Bolduc PL, Robinson RG: Depression in Parkinson’s disease. J Nerv Ment Dis 1990, 178:27–31.

    Article  PubMed  CAS  Google Scholar 

  3. Doonief G, Mirabello E, Bell K, et al.: An estimate of the incidence of depression in idiopathic Parkinson’s disease. Arch Neurol 1992, 49:305–307.

    Google Scholar 

  4. Cummings JL: Depression and Parkinson’s disease: a review. Am J Psychiatry 1992, 149:443–454.

    PubMed  CAS  Google Scholar 

  5. Tandberg E, Larsen JP, Aarsland D, Cummings JL: The occurrence of depression in Parkinson’s disease: a community-based study. Arch Neurol 1996, 53:175–179.

    PubMed  CAS  Google Scholar 

  6. Schrag A, Jahanshahi M, Quinn NP: What contributes to depression in Parkinson’s disease? Psychol Med 2001, 31:65–73. An important article on depression and PD.

    Article  PubMed  CAS  Google Scholar 

  7. Starkstein SE, Berthier ML, Bolduc PL: Depression in patients with early versus late onset of Parkinson’s disease. Neurology 1989, 39:1441–1445.

    PubMed  CAS  Google Scholar 

  8. Kostic VS, Filipovic SR, Lecic D, et al.: Effect of age on frequency of depression in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1994, 57:1265–1267.

    PubMed  CAS  Google Scholar 

  9. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, edn 4. Washington, DC; American Psychiatric Association: 1994.

    Google Scholar 

  10. Beck AT, Ward CH, Mendelson M, et al.: An inventory for measuring depression. Arch Gen Psychiatry 1961, 4:561–571.

    PubMed  CAS  Google Scholar 

  11. Dahlstrom W, Welsh G, Dahlstrom L: An MMPI Handbook: Clinical Interpretation, In vol 1. Minneapolis, MN: University of Minnesota Press; 1972.

    Google Scholar 

  12. Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967, 6:278–296.

    PubMed  CAS  Google Scholar 

  13. Montgomery SM: Depressive symptoms in acute schizophrenia. Progr Neuropsychopharmacol 1979, 3:429–433.

    Article  CAS  Google Scholar 

  14. Yesavage JA, Brink RL, Rose TL, et al.: Development and validation of a geriatric depression screening scale: a preliminary report. J Psych Res 1982, 17:37–49.

    Article  Google Scholar 

  15. Zung WWK: A self-rating depression scale. Arch Gen Psychiatry 1965, 12:63–70.

    PubMed  CAS  Google Scholar 

  16. Goldberg P: The Detection of Psychiatric Illness by Questionnaire: Maudsley Monograph 21. London: Oxford University Press; 1972.

    Google Scholar 

  17. Goldberg D: Manual of the General Health Questionnaire. Windsor, England: NFER-Nelson Press; 1978.

    Google Scholar 

  18. Levin BE, Llabre MM, Weiner WJ: Parkinson’s disease and depression: psychometric properties of the Beck Depression Inventory. J Neurol Neurosurg Psychiatry 1988, 51:1401–1404.

    PubMed  CAS  Google Scholar 

  19. Cimino CR, Zesiewicz TA, Soety E, et al.: Depression in Parkinson’s disease: degree of association and rate of agreement of clinician-based and self-report measures. Paper presented at the Symposia on Etiology, Pathogenesis, and Treatment of Parkinson’s Disease and Other Movement Disorders; September 30, 2001; Chicago, IL.

  20. Miyoshy K, Ueki A, Nagano O: Management of psychiatric symptoms of Parkinson’s disease. Eur Neurology 1996, 36:49–54.

    Google Scholar 

  21. Ellgring H, Seiler S, Nagel U, et al.: Psychosocial problems of Parkinson patients: approaches to assessment and treatment. Adv Neurol 1990, 53:349–353.

    PubMed  CAS  Google Scholar 

  22. Judd LL, Rapaport MH, Paulus MP et al.: Subsyndromal symptomatic depression: a new mood disorder? J Clin Psych 1994, 55(suppl):18–28.

    Google Scholar 

  23. Taylor AT, Saint-Cyr JA, Lang AE, Kenny FT: Parkinson’s disease and depression: a critical re-evaluation. Brain 1986, 109:279–292.

    Article  PubMed  Google Scholar 

  24. Huber SJ, Friedenberg DL, Paulson GW, et al.: The pattern of depressive symptoms varies with progression of Parkinson’s disease. J Neurol Neurosurg Psychiatry 1990, 53:275–278.

    PubMed  CAS  Google Scholar 

  25. Haltenhof H, Schroter C: Depression beim Parkinson-Syndrom: Eine Literatubersicht. Fortschr Neurol Psychiatr 1994, 62:94–101.

    PubMed  CAS  Google Scholar 

  26. Jackson JA, Free GBM, Pike HV: The psychic manifestations in paralysis agitans. Arch Neurol Psychiatry 1923, 8:680–684.

    Google Scholar 

  27. Mindham RH: Psychiatric symptoms in parkinsonism. J Neurol Neurosurg Psychiatry 1970, 33:188–191.

    PubMed  CAS  Google Scholar 

  28. Mayeux R, Stern Y, Rosen J, et al.: Depression, intellectual impairment, and Parkinson’s disease. Neurology 1981, 31:645–650.

    PubMed  CAS  Google Scholar 

  29. Hoehn MM, Yahr MD: Parkinsonism: onset, progression, and mortality. Neurology 1967, 50:318–334.

    Google Scholar 

  30. Meara J, Mitchelmore E, Hobson P: Use of the GDS-15 geriatric depression scale as a screening instrument for depressive symptomatology in patients with Parkinson’s disease and their carriers in the community. Age Aging 1999, 28:35–38.

    Article  CAS  Google Scholar 

  31. Celesia GG, Wanamaker WM: Psychiatric disturbances in Parkinson’s disease. Dis Nerv Sys 1972, 9:577–583.

    Google Scholar 

  32. Ehmann TS, Beninger RJ, Gawel MJ, Riopelle RJ: Depressive symptoms in Parkinson’s disease: a comparison with disabled control subjects. J Geriatr Psychiatry Neurol 1990, 2:3–9.

    Article  Google Scholar 

  33. Menza MA, Sage J, Marshall E, et al.: Mood changes and "on-off" phenomena in Parkinson’s disease. Mov Disord 1990, 5:148–151.

    Article  PubMed  CAS  Google Scholar 

  34. Cantello R, Gilli M, Riccio A, Bergamasco B: Mood changes associated with "end-of-dose deterioration" in Parkinson’s disease: a controlled study. J Neurol Neurosurg Psychiatry 1986, 49:1182–1190.

    PubMed  CAS  Google Scholar 

  35. Brown R, Marsden CD, Quinn N, Wyke MA: Alterations in cognitive performance and affect-arousal state during fluctuations in motor function in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1984, 47:454–465.

    Article  PubMed  CAS  Google Scholar 

  36. Laitinen L: Desipramine in treatment of Parkinson’s disease: a placebo-controlled study. Acta Neurol Scand 1969, 45:109–113.

    Article  PubMed  CAS  Google Scholar 

  37. Denmark JC, David JDP, McComb SG: Imipramine hydrocholride (tofranil) in parkinsonism: a preliminary report. Br J Clin Prac 1961, 15:523–524.

    CAS  Google Scholar 

  38. Andersen J, Aabro E, Gulman N, et al.: Anti-depressive treatment in Parkinson’s disease: a controlled trial of the effect of nortriptyline in patients with Parkinson’s disease treated with L-dopa. Acta Neurol Scand 1980, 62:210–219.

    Article  PubMed  CAS  Google Scholar 

  39. Dell’Agnello G, Ceravolo R, Nuti A, et al.: SSRIs do not worsen Parkinson’s disease: evidence from an open-label, prospective study. Clin Neuropharmacol 2001, 24:221–227. A good review.

    Article  PubMed  CAS  Google Scholar 

  40. Hauser RA, Zesiewicz TA: Sertraline for the treatment of depression in Parkinson’s disease. Mov Disord 1997, 12:756–759.

    Article  PubMed  CAS  Google Scholar 

  41. Meara J, Hobson P: Sertraline for the treatment of depression in Parkinson’s disease. Mov Disord 1998, 13:622.

    Article  PubMed  CAS  Google Scholar 

  42. Wittgens W, Donath O, Trenckmann U: Treatment of depressive syndromes in Parkinson’s disease with paroxetine. Mov Disord 1997, 12:128.

    Google Scholar 

  43. Tesei S, Antonini A, Canesi M, et al.: Tolerability of paroxetine in Parkinson’s disease: a prospective study. Mov Disord 2000, 15:986–989.

    Article  PubMed  CAS  Google Scholar 

  44. Ceravolo R, Nuti A, Piccinni A, et al.: Paroxetine in Parkinson’s disease: effects on motor and depressive symptoms. Neurology 2000, 55:1216–1218.

    PubMed  CAS  Google Scholar 

  45. Goetz CG, Tanner CM, Klawans HL: Bupropion in Parkinson’s disease. Neurology 1984, 34:1092–1094.

    PubMed  CAS  Google Scholar 

  46. Tate JL: Extrapyramidal symptoms in a patient taking haldoperidol and fluoxetine. Am J Psychiatry 1989, 146:399–400.

    PubMed  CAS  Google Scholar 

  47. Jimenez-Jimenez FJ, Tejeiro J, Martinez-Junquera G, et al.: Parkinsonism exacerbated by paroxetine. Neurology 1994, 44:2406.

    PubMed  CAS  Google Scholar 

  48. Bouchard RH, Pourcher E, Vincent P: Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1989, 146:1352–1353.

    Google Scholar 

  49. Linazasoro G: Worsening of Parkinson’s disease by citalopram. Parkinsonism Relat Disord 2000, 6:111–113.

    Article  PubMed  Google Scholar 

  50. Leo RU: Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 1996, 57:449–454.

    PubMed  CAS  Google Scholar 

  51. Cano A, Roqueer J: Parkinsonismo secundario al uso di sertralina. Medicina Clinica 1995, 105:797–798.

    PubMed  CAS  Google Scholar 

  52. Schecter DR, Nunes EV: Reversible parkinsonism in a 90-year-old man taking sertraline. J Clin Psychiatry 1997, 58:275.

    Google Scholar 

  53. Pina Latorra MA, Zabala Lopez S: Parkinsonismo reversible secundario a la toma de sertralina. Neurologia 1998, 13:444–445.

    Google Scholar 

  54. Latorre MA Pina, Modrego PJ, Rodilla F, et al.: Parkinsonism and Parkinson’s disease associated with long-term administration of sertraline. J Clin Phar Ther 2001, 26:111–112.

    Article  Google Scholar 

  55. Richard IH, Kurlan R: A survey of antidepressant drug use in Parkinson’s disease. Neurology 1997, 49:1168–1170.

    PubMed  CAS  Google Scholar 

  56. Montastruc JL, Fabre N, Blin O: Does fluoxetine aggravate Parkinson’s disease? A pilot prospective study. Mov Disord 1995, 10:355–356.

    Article  PubMed  CAS  Google Scholar 

  57. Caley CF, Friedman JH: Does fluoxetine exacerbate Parkinson’s disease? J Clin Psychiatry 1992, 53:278–282.

    PubMed  CAS  Google Scholar 

  58. Edwards JG, Anderson I: Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 1999, 57:507–533.

    Article  PubMed  CAS  Google Scholar 

  59. Richard IH, Maughn A, Kurlan R: Do serotonin reuptake inhibitor antidepressants worsen Parkinson’s disease? A retrospective case series. Mov Disord 1999, 14:155–193. An important review.

    Article  PubMed  CAS  Google Scholar 

  60. Radomski JW, Dursun SM, Reveley MA, Kutcher SP: An exploratory approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnostic criteria. Med Hypothesis 2000, 55:218–224.

    Article  CAS  Google Scholar 

  61. Sternbach H: The serotonin syndrome. Am J Psychiatry 1991, 148:705–713.

    PubMed  CAS  Google Scholar 

  62. Hinds NP, Hillier CEM, Wiles CM: Possible serotonin syndrome arising from an interaction between nortriptyline and selegiline in a lady with parkinsonism. J Neurol 2000, 247:811.

    Article  PubMed  CAS  Google Scholar 

  63. Waters CH: Fluoxetine and selegiline. Can J Neurol Sci 1994, 21:259–261.

    PubMed  CAS  Google Scholar 

  64. Toyama SC, Iacono RP: Is it safe to combine a selective serotonin reuptake inhibitor with selegiline? Ann Pharmacother 1994, 28:4045–406.

    Google Scholar 

  65. Richard I, Kurlan R, Tanne C, et al.: Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson’s disease: Parkinson study group. Neurology 1997, 48:1070–1077.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Parkinson’s Disease and Movement Disorders Center, University of South Florida College of Medicine, 4 Columbia Drive, Suite 410, 33606, Tampa, FL, USA

    Theresa A. Zesiewicz MD & Robert A. Hauser MD

Authors
  1. Theresa A. Zesiewicz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert A. Hauser MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zesiewicz, T.A., Hauser, R.A. Depression in Parkinson’s disease. Curr Psychiatry Rep 4, 69–73 (2002). https://doi.org/10.1007/s11920-002-0016-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11920-002-0016-7

Keywords

Search

Navigation